Safety, quality & regulatory

What we honestly know about KPV safety, and what we do not

KPV looks unremarkable in preclinical tolerability studies, but preclinical tolerability is not human safety. There is no systematic human safety monitoring, no validated dose, and KPV is not an FDA-approved product. Its regulatory paper trail is easy to misread, so this unit walks it slowly: KPV sat in the FDA's 503A category 2 compounding safety-risk group, then moved, with 11 other substances, onto the same page's list of nominations that the nominators withdrew. The FDA kept evaluating KPV at its own discretion and took it to the Pharmacy Compounding Advisory Committee on July 23, 2026, where its own briefing document concluded that a balancing of the criteria weighs against placing KPV on the 503A bulks list. The committee went the other way and recommended, by a narrow margin, that KPV be added. That recommendation is advice, not a rule: the FDA has not adopted it, no rulemaking has followed, and KPV is still not on the list. Product quality varies, and that variability can dominate any real-world experience.

This unit separates the reassuring parts from the genuine open questions, covers the US regulatory reality, and gives you a practical lens on sourcing red flags, all as education, not medical advice.